Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Corso Duca degli Abruzzi 24, 10129 Turin, Italy.
Department of Clinical Neurosciences, University of Cambridge, The Clifford Allbutt Building, Cambridge CB2 0AH, UK.
Biomed Res Int. 2018 Feb 21;2018:4518060. doi: 10.1155/2018/4518060. eCollection 2018.
Current therapeutic strategies to treat neurodegenerative diseases, such as alpha-synucleinopathies, aim at enhancing the amount of drug reaching the brain. Methods proposed, such as intranasal administration, should be able to bypass the blood brain barrier (BBB) and even when directly intracerebrally injected they could require a carrier to enhance local release of drugs. We have investigated the effect of a model synthetic hydrogel to be used as drug carrier on the amount of alpha-synuclein aggregates in cells in culture. The results indicated that alpha-synuclein aggregation was affected by the synthetic polymer, suggesting the need for testing the effect of any used material on the pathological process before its application as drug carrier.
目前治疗神经退行性疾病（如α-突触核蛋白病）的治疗策略旨在增加药物到达大脑的量。提出的方法，如鼻内给药，应该能够绕过血脑屏障（BBB），即使直接脑内注射，也可能需要载体来增强药物的局部释放。我们研究了一种模型合成水凝胶作为药物载体对培养细胞中α-突触核蛋白聚集物的量的影响。结果表明，合成聚合物影响α-突触核蛋白的聚集，这表明在将任何使用的材料用作药物载体之前，需要测试其对病理过程的影响。
